Effects of minimal-dose aprotinin on coronary artery bypass grafting

Journal of Thoracic and Cardiovascular Surgery

Volumn 114, Issue 2, 1997, Pages 261-269

  Hayashida, N ^a   Isomura, T ^a   Sato, T ^a   Maruyama, H ^a   Kosuga, K ^a   Aoyagi, S ^a  

^a KURUME UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; APROTININ; PLASMINOGEN ACTIVATOR;

ADULT; ANGIOGRAPHY; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; GRAFT PATENCY; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; VEIN GRAFT;

EID: 0030820616     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5223(97)70154-5     Document Type: Article

References (33)

1. D Royston BP Bidstrup KM Taylor RN. Sapsford Effect of aprotinin on need for blood transfusion after repeat open-heart surgery Lancet 2 1987 1289 1291
2. W van Oeveren NJG Jansen BP Bidstrup D Royston S Westaby H Neuhof Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass Ann Thorac Surg 44 1987 640 645
3. M Havel H Teufelsbauer P Knöbl R Dalmantiner P Jaksch W Zwölfer Effect of intraoperative aprotinin administration on postoperative bleeding in patients undergoing cardiopulmonary bypass operation J Thorac Cardiovasc Surg 101 1991 968 972
4. E Rocha F Hidalgo R Llorens JM Melero JL Arroyo JA. Paramo Randomized study of aprotinin and DDAVP to reduce postoperative bleeding after cardiopulmonary bypass surgery Circulation 90 1994 921 927
5. W van Oeveren MP Harder KJ Roozendaal L Eijsman CRH. Wildevuur Aprotinin protects against the initial effect of cardiopulmonary bypass J Thorac Cardiovasc Surg 99 1990 788 797
6. AAEA de Smet MCN Joen W van Oeveren KJ Roozendaal MP Harder L Eijsman Increased anticoagulation during cardiopulmonary bypass by aprotinin J Thorac Cardiovasc Surg 100 1990 520 527
7. M Kawasuji K Ueyama N Sakakibara T Tedoriya Y Matsunaga T Misaki Effect of low-dose aprotinin on coagulation and fibrinolysis in cardiopulmonary bypass Ann Thorac Surg 55 1993 1205 1209
8. B Liu L Tengborn G Larson LOG Radberg A Belboul L Dernevik Half-dose aprotinin preserves hemostatic function in patients undergoing bypass operations Ann Thorac Surg 59 1995 1534 1540
9. DM Cosgrove B Heric BW Lytle PC Taylor R Novoa LAR Golding Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study Ann Thorac Surg 54 1992 1031 1038
10. TM Sundt NT Kouchoukos JE Saffitz SF Murphy TH Wareing DJ. Stahl Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest Ann Thorac Surg 55 1993 1418 1424
11. S. Westaby Aprotinin in perspective Ann Thorac Surg 55 1993 1033 1041
12. JH. Lemmer Reporting the results of blood conservation studies: the need for uniform and comprehensive methods Ann Thorac Surg 58 1994 1305 1306
13. MF Scully VV. Kakkar Methods for semi micro or automated determination of thrombin, antithrombin, and heparin cofactor using the substrate, H-d-Phe-Pip-Arg-p-nitroanilide · 2HCl Clin Chim Acta 79 1977 595 602
14. P Friberger M Knös S Gustavsson L Aurell G. Claeson Methods for determination of plasmin, antiplasmin and plasminogen by means of substrate S-2251 Haemostasis 7 1978 138 145
15. VA. Clauss Rapid physiological coagulation method for the determination of fibrinogen Acta Haematol 17 1957 237 246
16. M Toyokawa E Suehisa K Nishimura M Suetomo K Kouda N Amino Fundamental study and clinical efficacy of thrombin-antithrombin III complex [in Japanese] Igaku Yakugaku 23 1990 959 966
17. P Declerck MC Alessi M Verstreken EKO Kruithof I Juhan-Vague D. Collen Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody based enzyme-linked immunosorbent assay Blood 71 1988 220 225
18. MJ Elms IH Bunce PG Bundessen DB Rylatt AJ Webber PP Masci Measurement of crosslinked fibrin degradation products: an immunoassay using monoclonal antibodies Thromb Haemostas 50 1983 591 594
19. B Blauhut C Gross S Necek JE Doran P Späth P. Lundsgaard-Hansen Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass J Thorac Cardiovasc Surg 101 1991 958 967
20. JH Fischer P. Knupfer High dose aprotinin (Trasylol) therapy: harmless to the kidney Langenbecks Arch Chir 360 1983 241 249
21. JH. Fischer Effects of Trasylol on the kidneys: dependence on temperature and dose R Dudziak HD Reuter PG Kirchoff F Schumann Proteolysis and proteinase inhibitor in cardiac and vascular surgery. 1985 Schattauer Verlag Stuttgart 127 135
22. E Covino P Pepino D Iorio L Marino P Ferrara N. Spampinato Low dose aprotinin as blood saver in open heart surgery Eur J Cardiothorac Surg 5 1991 414 418
23. DM Najman JM Walenga J Fareed R. PifarrÉ Effects of aprotinin on anticoagulant monitoring: implications in cardiovascular surgery Ann Thorac Surg 55 1993 662 666
24. BJ Hunt HC Segal M. Yacoub Guidelines for monitoring heparin by the activated clotting time when aprotinin is used during cardiopulmonary bypass [letter] J Thorac Cardiovasc Surg 1134 1992 211 212
25. H Bohrer F Fleischer J Lang C. Vahr Early formation of thrombi on pulmonary artery catheters in cardiac surgical patients receiving high-dose aprotinin J Cardiothorac Anesth 4 1990 222 225
26. JA. Youngberg Aprotinin and thrombus formation on pulmonary artery catheters: a piece of the coagulation puzzle J Cardiothorac Anesth 4 1990 155 158
27. BP Bidstrup SR Underwood RN. Sapsford Effect of aprotinin (Trasylol) on aorta-coronary bypass graft patency J Thorac Cardiovasc Surg 105 1993 147 153
28. JH Lemmer W Stanford SL Bonney JF Breen EV Chomka WJ Eldredge Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency—a multicenter, randomized, double-blind, placebo-controlled study J Thorac Cardiovasc Surg 107 1994 543 553
29. M Havel F Grabenwöger J Schneider G Laufer G Wollenek A Owen Aprotinin does not decrease early graft patency after coronary bypass grafting despite reducing postoperative bleeding and use of donated blood J Thorac Cardiovasc Surg 107 1994 807 810
30. JH Levy R PifarrÉ HV Schaff JC Horrow R Albus B Spiess A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting Circulation 92 1995 2236 2244
31. H Tatar S Cicek U Demirkilic E Özal H Süer Ö Öztürk Topical use of aprotinin in open heart operations Ann Thorac Surg 55 1993 659 661
32. DJ O'Regan N Giannopoulos N Mediratta SWH Kendall A Forni R Pillai Topical aprotinin in cardiac operations Ann Thorac Surg 58 1994 778 781
33. N Tabuchi J de Haan W. van Oeveren Topical effect of aprotinin on the surgical wound in cardiac surgery J Thorac Cardiovasc Surg 109 1995 399 400